Activation of regulatory t cells by alpha-melanocyte stimulating hormone
CA 2359636 A1 · Owner: The Schepens Eye Research Institute, Inc. · Inventors: Taylor, Andrew W.; Nishida, Tomomi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention encompasses a method of down-regulating a T cell-mediated immune response, through activation or T cell receptor (TCR) stimulation of antigenprimed T cells in the presence of alpha-melanocyte stimulating hormone (.alpha.-MSH), which may be optionally enhanced by adding transforming growth factor-.beta.2 (TGF-.beta.2) approximately 4-6 hours after the start of the primed T cells' exposure to .alpha.-MSH. Activation of the primed T cells may be mediated by presentation of the specific antigen to the primed T cells or , by an anti-TCR antibody or a T cell mitogen. As a result of the .alpha.-MSH treatment modulating the T cell activation antigen-specific, regulatory, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 21, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 21, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 21, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.